Recently, an emergence of non-statin alternatives including omega-3 fatty acid-based products have demonstrated reduction in important cardiovascular endpoints. Where do these agents fit in patient care? Join us this month for our Journal Club discussion on how icosapent ethyl compares to other non-statin alternatives and previous literature examining use of omega-3 fatty acids.

Upon successful completion of this application-based course, pharmacists should be able to:
1. Based on the inclusion and exclusion criteria of REDUCE-IT, identify an appropriate candidate for icosapent ethyl.
2. Counsel a patient on the use icosapent ethyl including dosing, adverse effects and expected benefits and risks.
3. Compare other non-statin alternatives including PCSK9 inhibitors and ezetimibe with regard to the clinical efficacy when added to statin based regimens.
4. Discuss strengths and limitations of the REDUCE-IT trial.
5. Discuss how the REDUCE-IT trial compares to previous trials that have examined omega-3 fatty acid based products.

Matthew Cantrell, PharmD, BCPS
Clinical Associate Professor
University of Iowa College of Pharmacy

Matthew Cantrell does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: August 12, 2020
Planned Expiration Date: August 12, 2023